← Leaderboards
M. Maral Mouradian
Neurological Disorders And Stroke
$10,617,332
Attributed
$15,600,585
Total exposure
13
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,600,585 · 13
By mechanism
R01$8,575,578 · 4
R21$1,714,941 · 4
RF1$1,653,093 · 1
T32$1,440,014 · 1
UH3$851,067 · 1
R33$843,131 · 1
Top collaborators
- Stella M Papa6 shared
- Jeffry B Stock6 shared
- Matthew D Disney5 shared
- Russell E Nicholls5 shared
- Stephen F Vatner1 shared
Most similar at Neurological Disorders And Stroke
Same institution · by research overlap
- David R. Sibley$6,075
Others in their field
Top investigators on “Neurons”
- Hongkui Zeng · Allen Institute$106,358,289
- Eric Martin McDade · Washington University$94,632,845
- Ed Lein · Allen Institute$90,858,363
- Randall J Bateman · Washington University$65,841,935
- John Morris · Washington University$65,018,684
- Paul S. Aisen · Cognition Therapeutics, Inc.$58,570,460
Research focus
NeuronsBrainProteinsMolecularParkinson DiseasePlayCellsMediatingLeadIn VivoAlpha SynucleinLinkBrain CellGenesAnimal ModelEventMouse ModelPathogenesisSynucleinopathyChronicTechnologyCell ModelPathologyAnimals
Grant awards (41)
Training in Translating Neuroscience to Therapies$336,961
T32 · FY2025 · NS · contact PI
Training in Translating Neuroscience to Therapies$262,922
T32 · FY2024 · NS · contact PI
PME-1: Pathogenetic Role and Therapeutic Opportunity in Neurodegenerative Mixed Proteinopathies$1,653,093
RF1 · FY2023 · NS · contact PI
Training in Translating Neuroscience to Therapies$326,482
T32 · FY2023 · NS · contact PI
Alzheimerâs Disease Protection by Reduced Adenylyl Cyclase Type 5$431,750
R21 · FY2022 · AG
Training in Translating Neuroscience to Therapies$315,682
T32 · FY2022 · NS · contact PI
RNA Targeted Drug Discovery and Development for Parkinson Disease$851,067
UH3 · FY2021 · NS · contact PI
Role of Transglutaminase 2 in Synucleinopathies$431,750
R21 · FY2021 · NS · contact PI
PP2A Dysregulation in the Pathogenesis of alpha-Synucleinopathies$411,687
R01 · FY2021 · NS · contact PI
Training in Translating Neuroscience to Therapies$197,967
T32 · FY2021 · NS · contact PI
RNA Targeted Drug Discovery and Development for Parkinson Disease$522,761
UG3 · FY2020 · NS · contact PI
PP2A Dysregulation in the Pathogenesis of alpha-Synucleinopathies$451,511
R01 · FY2020 · NS · contact PI
Developing Novel RNA-Based Therapeutics for Parkinson's Disease$424,450
R33 · FY2019 · NS · contact PI
PP2A Dysregulation in the Pathogenesis of alpha-Synucleinopathies$415,807
R01 · FY2019 · NS · contact PI
PP2A Dysregulation in the Pathogenesis of alpha-Synucleinopathies$504,636
R01 · FY2018 · NS · contact PI
Developing Novel RNA-Based Therapeutics for Parkinson's Disease$418,681
R33 · FY2018 · NS · contact PI
PP2A Dysregulation in the Pathogenesis of alpha-Synucleinopathies$526,942
R01 · FY2017 · NS · contact PI
Developing Novel RNA-Based Therapeutics for Parkinson's Disease$452,438
R21 · FY2017 · NS · contact PI
Synergistic Neuroprotective Mechanisms of Coffee Components in Parkinson's Diseas$414,894
R01 · FY2016 · AT · contact PI
Manipulating Gene Expression in the Dyskinesias of Parkinson's Disease$47,979
R01 · FY2016 · NS
Manipulating Gene Expression in the Dyskinesias of Parkinson's Disease$441,026
R01 · FY2015 · NS
Synergistic Neuroprotective Mechanisms of Coffee Components in Parkinson's Diseas$416,027
R01 · FY2015 · AT · contact PI
Manipulating Gene Expression in the Dyskinesias of Parkinson's Disease$443,793
R01 · FY2014 · NS
Synergistic Neuroprotective Mechanisms of Coffee Components in Parkinson's Diseas$429,017
R01 · FY2014 · AT · contact PI
Manipulating Gene Expression in the Dyskinesias of Parkinson's Disease$462,020
R01 · FY2013 · NS
Synergistic Neuroprotective Mechanisms of Coffee Components in Parkinson's Diseas$441,566
R01 · FY2013 · AT · contact PI
Manipulating Gene Expression in the Dyskinesias of Parkinson's Disease$470,609
R01 · FY2012 · NS
Synergistic Neuroprotective Mechanisms of Coffee Components in Parkinson's Diseas$303,499
R01 · FY2012 · AT · contact PI
Synergistic Neuroprotective Mechanisms of Coffee Components in Parkinson's Diseas$179,197
R01 · FY2012 · AT · contact PI
Manipulating Gene Expression in the Dyskinesias of Parkinson's Disease$505,150
R01 · FY2011 · NS
Neuroprotective Activity of DJ-1 in Parkinson's Disease$334,425
R01 · FY2011 · NS · contact PI
Neuroprotective Activity of DJ-1 in Parkinson's Disease$337,838
R01 · FY2010 · NS · contact PI
Neuroprotective Activity of DJ-1 in Parkinson's Disease$355,455
R01 · FY2009 · NS · contact PI
Neuroprotective Activity of DJ-1 in Parkinson's Disease$341,250
R01 · FY2008 · NS · contact PI
Neuroprotective Activity of DJ-1 in Parkinson's Disease$341,250
R01 · FY2007 · NS · contact PI
Anti-apoptotic Function of DJ-1 in Parkinson's Disease$224,065
R21 · FY2007 · NS · contact PI
Anti-apoptotic Function of DJ-1 in Parkinson's Disease$174,938
R21 · FY2006 · NS · contact PI
Molecular Pathogenesis Of Cell Death In Neurodegenerativ$0
Z01 · FY2004 · NS
Molecular Pathogenesis Of Cell Death In Neurodegenerativ$0
Z01 · FY2003 · NS
Molecular Pathogenesis Of Cell Death In Neurodegenerativ$0
Z01 · FY2002 · NS
MOLECULAR PATHOGENESIS OF CELL DEATH IN NEURODEGENERATIVE DISEASES$0
Z01 · FY2000 · NS